Author name: Leonardo Arias

Capacity at the company’s Boston site will increase by 50% as part of a $600 million, 10-year commitment to the U.S.

The deal gives the customer experience firm access to Press Ganey’s extensive healthcare data to bolster artificial intelligence capabilities.

The plaintiffs argue that speech in certain healthcare settings ought to be protected by the First Amendment. Critics say that sets a dangerous precedent, where providers can offer debunked or harmful medical advice with impunity.

MedSec CEO Michelle Jump spoke with MedTech Dive at AdvaMed’s annual meeting about the FDA’s shift from a “carrot” to a “stick” approach in cybersecurity regulation.

At AdvaMed’s The MedTech Conference, executives said they’re incorporating AI in more devices, but figuring out how to use the technology internally is more challenging.

Amgen will offer its lipid-lowering drug Repatha directly to patients for $239 per month, representing a nearly 60% reduction from the current wholesale acquisition cost of $527.70.

Skye Bioscience’s nimacimab fell short of investor and company expectations, but showed encouraging weight-loss results when combined with Wegovy, according to analysts at William Blair.

Of the three highest bidders, Pfizer’s purchase proposal for Metsera was the lowest, regulatory documents reveal. The New York pharma, however, offered the smoothest transaction with the greatest likelihood of success.

The inaugural 40 Under 40 cohort includes CEOs, leaders who have founded or co-founded their company and executives from a range of disciplines. Winners’ accomplishments include shaping drug development, achieving key FDA milestones and launching a new field of study.

A new survey from CRB showed that most manufacturing initiatives in the U.S. made in response to tariffs are coming from Big Pharma companies, while smaller biotechs are left to hope “the situation doesn’t get worse.”